Teva Pharma (TEVA) Tops Q2 EPS by 12c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Teva Pharma (TEVA) Shares Surge on Proposed Opioid Settlement, Earnings Beat
July 27, 2022 11:44 AM EDTShares of Teva Pharma (NYSE: TEVA) jumped over 24% in early Wednesday trading following the announcement of its second-quarter results and an agreement, in principle, on a nationwide opioid settlement.
The company beat earnings and revenue forecasts, posting a profit of $0.68 per share on revenue of $3.79 billion. Analysts expected earnings per share of $0.56 on revenue of $3.78 billion.
However, it is the company's opioid settlement announcement that has caught the attention of... More
